Aster DM Healthcare reports solid Q3 FY26 growth, combined proforma revenue up 15%
On a proforma basis in Q3 FY26, revenues grew by 15% YoY to Rs. 2,366 Cr and operating EBITDA increased by 22% YoY to Rs. 503 Cr
On a proforma basis in Q3 FY26, revenues grew by 15% YoY to Rs. 2,366 Cr and operating EBITDA increased by 22% YoY to Rs. 503 Cr
CSPC will receive an upfront $1.2 billion from AstraZeneca for access to eight programmes, AI molecular design capabilities, and the LiquidGel platform
The company’s total income jumped 31% year-on-year to Rs 125.5 crore
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
The base Gland business posted ?11,790 million in revenue, up 16% YoY
The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio
Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
Subscribe To Our Newsletter & Stay Updated